- Home
- NCV vs NMRA Comparison
NCV vs NMRA Comparison
Compare NCV & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- NMRA
- Stock Information
- Founded
- NCV 2003
- NMRA 2019
- Country
- NCV United States
- NMRA United States
- Employees
- NCV N/A
- NMRA N/A
- Industry
- NCV Finance Companies
- NMRA
- Sector
- NCV Finance
- NMRA
- Exchange
- NCV Nasdaq
- NMRA Nasdaq
- Market Cap
- NCV 326.0M
- NMRA 268.5M
- IPO Year
- NCV N/A
- NMRA 2023
- Fundamental
- Price
- NCV $14.84
- NMRA $1.68
- Analyst Decision
- NCV
- NMRA Buy
- Analyst Count
- NCV 0
- NMRA 8
- Target Price
- NCV N/A
- NMRA $7.14
- AVG Volume (30 Days)
- NCV 405.1K
- NMRA 444.5K
- Earning Date
- NCV 01-01-0001
- NMRA 08-06-2025
- Dividend Yield
- NCV 12.48%
- NMRA N/A
- EPS Growth
- NCV N/A
- NMRA N/A
- EPS
- NCV N/A
- NMRA N/A
- Revenue
- NCV N/A
- NMRA N/A
- Revenue This Year
- NCV N/A
- NMRA N/A
- Revenue Next Year
- NCV N/A
- NMRA N/A
- P/E Ratio
- NCV N/A
- NMRA N/A
- Revenue Growth
- NCV N/A
- NMRA N/A
- 52 Week Low
- NCV $2.84
- NMRA $0.61
- 52 Week High
- NCV $3.59
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- NCV 66.39
- NMRA 52.17
- Support Level
- NCV $14.65
- NMRA $1.69
- Resistance Level
- NCV $14.80
- NMRA $1.84
- Average True Range (ATR)
- NCV 0.15
- NMRA 0.10
- MACD
- NCV 0.01
- NMRA -0.01
- Stochastic Oscillator
- NCV 79.10
- NMRA 43.64
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.